C. Deleuze-Masquéfa

F. Pinguet, F. Bressolle, J. Cooper, 2010, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

EAPB0503, an Imidazoquinoxaline Derivative Modulates SENP3/ARF Mediated SUMOylation, and Induces NPM1c Degradation in NPM1 Mutant AML

R. Hleihel, H. El Hajj, P. Bonnet, 2022, International journal of molecular sciences.

Imidazo[1,2-a]quinoxalines: synthesis and cyclic nucleotide phosphodiesterase inhibitory activity.

J. Vidal, P. Bonnet, A. Michel, 2001, European journal of medicinal chemistry.

Substantial Cellular Penetration of Fluorescent Imidazoquinoxalines

P. Cuq, P. Bonnet, C. Deleuze-Masquéfa, 2020, Journal of Fluorescence.

Imidazo[1,2-a]quinoxalines Derivatives Grafted with Amino Acids: Synthesis and Evaluation on A375 Melanoma Cells

P. Cuq, P. Bonnet, C. Deleuze-Masquéfa, 2018, Molecules.

Imidazo[1,2-a]pyrazine, Imidazo[1,5-a]quinoxaline and Pyrazolo[1,5-a]quinoxaline derivatives as IKK1 and IKK2 inhibitors.

P. Cuq, I. Kassab, P. Bonnet, 2017, European journal of medicinal chemistry.

Design and synthesis of novel imidazo[1,2-a]quinoxalines as PDE4 inhibitors.

M. Strub, J. Fabréguettes, Grégori Gerebtzoff, 2004, Bioorganic & medicinal chemistry.

Impairment of TNF-α Production and Action by Imidazo[1,2- α] Quinoxalines, as Derivative Family Which Displays Potential Anti-Inflammatory Properties

P. Bonnet, V. Lafont, S. Morjaria, 2006, International journal of immunopathology and pharmacology.

Structural characterization of in vitro metabolites of the new anticancer agent EAPB0503 by liquid chromatography-tandem mass spectrometry.

F. Bressolle, C. Enjalbal, I. Solassol, 2014, Journal of pharmaceutical and biomedical analysis.

Lipid nanocapsules formulation and cellular activities evaluation of a promising anticancer agent: EAPB0503

J. Devoisselle, P. Cuq, A. Aubert-Pouëssel, 2017, International journal of pharmaceutical investigation.

1-[1-(2-Benzo[b]thiopheneyl)cyclohexyl]piperidine hydrochloride (BTCP) yields two active primary metabolites in vivo. Identification and quantification of BTCP primary metabolites in mice plasma, urine, and brain and their affinity for the neuronal dopamine transporter.

J. Vignon, J. Kamenka, C. Deleuze-Masquéfa, 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

1-[1-2-Benzo[b]thiopheneyl)cyclohexyl]piperidine hydrochloride (BTCP) yields two active primary metabolites in vitro: synthesis, identification from rat liver microsome extracts, and affinity for the neuronal dopamine transporter.

J. Vignon, J. Kamenka, C. Deleuze-Masquéfa, 1997, Journal of medicinal chemistry.

[1,2,4]triazolo[4,3-a]quinoxaline as Novel Scaffold in the Imiqualines Family: Candidates with Cytotoxic Activities on Melanoma Cell Lines

P. Bonnet, C. Deleuze-Masquéfa, C. Patinote, 2023, Molecules.

Lipid nanocapsules formulation and cellular activities evaluation of a promising anticancer agent: EAPB0503

J. Devoisselle, P. Cuq, A. Aubert-Pouëssel, 2017, International journal of pharmaceutical investigation.

New imidazoquinoxaline derivatives: Synthesis, biological evaluation on melanoma, effect on tubulin polymerization and structure-activity relationships.

N. Bec, C. Larroque, P. Cuq, 2016, Bioorganic & medicinal chemistry.

EAPB0503, a novel imidazoquinoxaline derivative, inhibits growth and induces apoptosis in chronic myeloid leukemia cells

R. Nasr, F. Mahon, A. Bazarbachi, 2014, Anti-cancer drugs.

Quantitation of imidazo[1,2-a]quinoxaline derivatives in human and rat plasma using LC/ESI-MS.

F. Pinguet, F. Bressolle, I. Solassol, 2009, Journal of separation science.

Methylation of imidazopyrazine, imidazoquinoxaline, and pyrazoloquinoxaline through Suzuki–Miyaura cross coupling

P. Cuq, I. Kassab, P. Bonnet, 2018, Chemistry of Heterocyclic Compounds.